Ampolini E, Jimenez-Sainz J, Long D
Target Oncol. 2025; .
PMID: 40024979
DOI: 10.1007/s11523-025-01136-6.
Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S
Sci Rep. 2025; 15(1):4294.
PMID: 39905117
PMC: 11794704.
DOI: 10.1038/s41598-024-82218-9.
Curti L, Rohban S, Bianchi N, Croci O, Andronache A, Barozzi S
Nat Commun. 2024; 15(1):7100.
PMID: 39155303
PMC: 11330984.
DOI: 10.1038/s41467-024-51229-5.
Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S
bioRxiv. 2024; .
PMID: 38895265
PMC: 11185620.
DOI: 10.1101/2024.06.04.596911.
Palumbieri M, Merigliano C, Gonzalez-Acosta D, Kuster D, Krietsch J, Stoy H
Nat Commun. 2023; 14(1):7819.
PMID: 38016948
PMC: 10684888.
DOI: 10.1038/s41467-023-43183-5.
Targeting ATR in Cancer Medicine.
Salguero C, Valladolid C, Robinson H, Smith G, Yap T
Cancer Treat Res. 2023; 186:239-283.
PMID: 37978140
DOI: 10.1007/978-3-031-30065-3_14.
A DNA Replication Stress-Based Prognostic Model for Lung Adenocarcinoma.
Shi S, Wen G, Lei C, Chang J, Yin X, Liu X
Acta Naturae. 2023; 15(3):100-110.
PMID: 37908773
PMC: 10615186.
DOI: 10.32607/actanaturae.25112.
Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles.
Hoffman T, Nangia V, Ill C, Passanisi V, Armstrong C, Yang C
Sci Signal. 2023; 16(796):eade8744.
PMID: 37527351
PMC: 10704347.
DOI: 10.1126/scisignal.ade8744.
DNA replication: Mechanisms and therapeutic interventions for diseases.
Song H, Shen R, Mahasin H, Guo Y, Wang D
MedComm (2020). 2023; 4(1):e210.
PMID: 36776764
PMC: 9899494.
DOI: 10.1002/mco2.210.
Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy.
Anand J, Chiou L, Sciandra C, Zhang X, Hong J, Wu D
NAR Cancer. 2023; 5(1):zcad005.
PMID: 36755961
PMC: 9900426.
DOI: 10.1093/narcan/zcad005.
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides.
Vedenkin A, Stovbun S, Bukhvostov A, Zlenko D, Stovbun I, Silnikov V
Invest New Drugs. 2023; 41(1):153-161.
PMID: 36749469
DOI: 10.1007/s10637-023-01333-y.
Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer.
Zhang J, Chan D, Lin S
Biomedicines. 2022; 10(11).
PMID: 36359297
PMC: 9687274.
DOI: 10.3390/biomedicines10112775.
Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic.
Zhang Y, Wu L, Wang Z, Wang J, Roychoudhury S, Tomasik B
Front Oncol. 2022; 12:838637.
PMID: 35875060
PMC: 9305609.
DOI: 10.3389/fonc.2022.838637.
p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways.
Lindstrom M, Bartek J, Maya-Mendoza A
Cell Death Differ. 2022; 29(5):972-982.
PMID: 35444234
PMC: 9090812.
DOI: 10.1038/s41418-022-00999-w.
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.
Labrie M, Brugge J, Mills G, Zervantonakis I
Nat Rev Cancer. 2022; 22(6):323-339.
PMID: 35264777
PMC: 9149051.
DOI: 10.1038/s41568-022-00454-5.
Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.
Karukonda P, Odhiambo D, Mowery Y
Mol Carcinog. 2021; 61(2):225-238.
PMID: 34964992
PMC: 8799519.
DOI: 10.1002/mc.23384.
The Safe Path at the Fork: Ensuring Replication-Associated DNA Double-Strand Breaks are Repaired by Homologous Recombination.
Nickoloff J, Sharma N, Taylor L, Allen S, Hromas R
Front Genet. 2021; 12:748033.
PMID: 34646312
PMC: 8502867.
DOI: 10.3389/fgene.2021.748033.
Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.
Pal R, Rajpal V, Singh P, Saraf S
Pharmaceutics. 2021; 13(6).
PMID: 34067322
PMC: 8224699.
DOI: 10.3390/pharmaceutics13060775.
in Chromosome Stability and Cell Survival-Is It All about Replication Forks?.
Hudson J, Rass U
Int J Mol Sci. 2021; 22(8).
PMID: 33924313
PMC: 8069077.
DOI: 10.3390/ijms22083984.